71 results
8-K
EX-99.1
PTCT
PTC Therapeutics Inc
25 Jan 24
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
4:06pm
early childhood and leads to premature death in the mid-20's due to heart and respiratory failure. It is a progressive muscle disorder caused
8-K
EX-10.1
PTCT
PTC Therapeutics Inc
22 Sep 23
Other Events
9:00am
(j), as a result of the termination, death or disability of such employee, director, manager or consultant.
“Disqualified Institution” means
8-K
EX-99.1
thq3wv
15 Sep 23
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
6:15am
8-K
EX-10.1
l9935mi417q
17 Jul 23
Departure of Directors or Certain Officers
4:46pm
8-K
EX-99.1
8371f 9ncbcxckgy6
21 Jun 23
Regulation FD Disclosure
7:30am
8-K
EX-99.2
2nk eicbjrgaus3x1z
21 Jun 23
Regulation FD Disclosure
7:30am
8-K
EX-99.2
rcec8fee7gu4xbyj
23 May 23
PTC Therapeutics Announces Strategic Pipeline Prioritization
5:17pm
8-K
EX-10.1
u1syahihdpzppw2yyl
18 Apr 23
Departure of Directors or Certain Officers
5:11pm
8-K
EX-3.1
ibxq9vt5y0ezz92b9mjl
6 Dec 22
Departure of Directors or Certain Officers
4:15pm
8-K
EX-99.1
2moobc4nm8mpr5
7 Sep 22
PTC 2022 Corporate Presentation September 2022
7:31am
8-K
EX-99.1
lps16sgcl97d2m 0jd
21 Jun 22
Translarna™(Ataluren)Study 041 Topline Results21stJune 2022
8:15am
8-K
EX-10.1
t5xt295m nmys0
9 Jun 22
Departure of Directors or Certain Officers
9:15am
8-K
EX-99.1
bodjku f5
9 Jun 22
Departure of Directors or Certain Officers
9:15am